New combo therapy targets Hard-to-Treat cancers with gene loss
Disease control
Recruiting now
This study tests a new oral drug, TNG462, combined with other treatments for people with pancreatic or non-small cell lung cancer that has lost the MTAP gene. The goal is to find safe doses and see if the combinations shrink tumors. About 183 adults with advanced or metastatic di…
Phase: PHASE1, PHASE2 • Sponsor: Tango Therapeutics, Inc. • Aim: Disease control
Last updated May 03, 2026 15:19 UTC